tradingkey.logo
tradingkey.logo
Search

Caplyta® (Lumateperone) Showed Greatest Improvement Across Key Efficacy Outcomes Among Adjunctive Mdd Treatments In New Network Meta-Analysis

ReutersMay 4, 2026 12:12 PM
facebooktwitterlinkedin
View all comments0

- Johnson & Johnson JNJ.N:

  • CAPLYTA® (LUMATEPERONE) SHOWED GREATEST IMPROVEMENT ACROSS KEY EFFICACY OUTCOMES AMONG ADJUNCTIVE MDD TREATMENTS IN NEW NETWORK META-ANALYSIS

  • JJ - CAPLYTA SHOWS NO WEIGHT GAIN COMPARED TO PLACEBO PLUS ANTIDEPRESSANT THERAPY

  • JJ - CAPLYTA HAS 100% PROBABILITY OF SUPERIORITY ON MEAN WEIGHT CHANGE VERSUS ALL COMPARATORS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI